Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response
CA 2747376 A1 · Owner: Brigham And Women'S Hospital · Inventors: Serhan, Charles N.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNF.alpha.)-initiated neutrophil (PMN) responses in vitro , and in vivo using metabolically stable LX analogs. At concentrations as low as 1 to 10 nM, the LXA4 and ATL analogs each inhibited TNF.alpha.-stimulated superoxide anion generation and , IL-1.beta. release by human PMN.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 14, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 14, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 14, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.